<DOC>
	<DOCNO>NCT00307840</DOCNO>
	<brief_summary>The purpose study compare two different initial dose scheme administration paricalcitol hemodialysis patient secondary hyperparathyroidism : already use iPTH/80 scheme , iPTH/120 scheme , correspond immediately low dose , base current instruction paricalcitol dose adjustment . We study effectiveness two dose scheme achieve target iPTH level ( 150 – 300 pg/mL )</brief_summary>
	<brief_title>Initial Dosing Paricalcitol Secondary Hyperparathyroidism</brief_title>
	<detailed_description>Adjustment initial dose paricalcitol , hemodialysis patient secondary hyperparathyroidism ( sHPT ) , basis severity sHPT generally prefer current practice . Whether propose dose , base formula baseline intact parathyroid hormone ( iPTH [ pg/mL ] ) divide 80 , appropriate adequately assess . A trial compare iPTH/80 dose immediately low iPTH/120 dose undertaken . We study ability two different dose scheme control iPTH level within desire range 150 300 pg/mL , well frequency iPTH over-suppression ( &lt; 150 pg/mL ) two group ( iPTH/80 iPTH/120 ) .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>maintenance hemodialysis therapy ( 3 session per week ) least 3 month ; iPTH 300 900 pg/mL ; age &gt; 18 year ; normal serum calcium concentration ( 8.1 10.4 mg/dL ) ; Ca x P product le 70 ; vitamin D metabolite replacement therapy least one month prior enrollment ; aluminum level low 60 μg/L . administration calcitonin , disphosphonates corticosteroid ; presence clinically serious medical condition ; previous parathyroidectomy ; active malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>hemodialysis ; secondary hyperparathyroidism ; hypercalcemia ; hyperphosphatemia ; vitamin D</keyword>
</DOC>